Developing a complex intervention for the outpatient management of incidentally diagnosed pulmonary embolism in cancer patients by June Palmer et al.
Palmer et al. BMC Health Services Research 2013, 13:235
http://www.biomedcentral.com/1472-6963/13/235TECHNICAL ADVANCE Open AccessDeveloping a complex intervention for the
outpatient management of incidentally
diagnosed pulmonary embolism in cancer
patients
June Palmer1, George Bozas1*, Andrew Stephens2, Miriam Johnson3, Ged Avery2, Lorcan O’Toole1 and
Anthony Maraveyas1,3Abstract
Background: Most patients with pulmonary embolism (PE) spend 5–7 days in hospital even though only 4.5% will
develop serious complications during this time. In particular, the group of patients with incidentally diagnosed PE
(i-PE) includes many patients with low risk features potentially ideal for outpatient management; however the
evidence for their optimal management is lacking hence relative practices may vary considerably. We describe the
development process, components, links and function of a nurse-led service for the management of patients with
i-PE, developed in accordance to the UK Medical Research Council complex intervention guidance.
Methods: Phase 0 (Theoretical underpinning): The Pulmonary Embolism Severity Index (PESI) was selected for patient
risk assessment and the American Society of Clinical Oncology (ASCO) guideline for the management of PE in
cancer patients (2007) was selected as quality measure. Historical registry and audit data from our centre regarding
i-PE incidence and management for the period between 2006 and 2009 illustrating the then current practices were
reviewed. Phase 1 (Modelling): Modelling of the pathway included the following: a) Identification of training needs,
planning and implementation of training schemes and development of transferable competencies and training
materials. b) Mapping patient pathways and flow and c) Production of key documentation and Standard Operating
Procedures for the delivery of the service.
Results: Phase 2 (Implementation and testing of the intervention): During the initial 12 months of implementation,
remedial action was taken to address identified deficiencies regarding patient referral to the pathway, compliance
with treatment protocol, patient follow up, selection challenges from the use of PESI in cancer patients and
challenges regarding the “first-pass” identification of i-PE.
Conclusion: We have developed and piloted a complex intervention to manage cancer patients with incidental PE
in an outpatient setting. Adherence to evidence- based care, improvement of communication between
professionals and patients, and improved quality of data is demonstrated.
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The Venous Thromboembolism (VTE) syndrome comprises
deep vein thrombosis (DVT) and pulmonary embolism (PE)
[1] and is particularly prevalent amongst cancer patients [2].
It is recognized that thrombosis and cancer are linked by
multiple physiopathological mechanisms and that tumour
biology and coagulation processes are integrally connected
[3]. Therapeutic interventions including surgery and chemo-
therapy further increase the risk for thrombosis. Despite
this being common knowledge the true prevalence of VTE
is underestimated as clinical presentation may be truly
asymptomatic and/or misattributed as well as the more
recognised symptoms and signs of thrombosis [4,5].
The recent improvement in imaging technology, through
the introduction of multi-slice spiral computed tomography
(CT) scans, and the more frequent whole body imaging of
patients with cancer due to the expansion in treatment
options and trials, has led to an increasing incidence of
incidental diagnosis of DVT or PE [6]. According to the
official statement of the subcommittee on Haemostasis
and Malignancy of the SCC of the International Society on
Thrombosis and Haemostasis, incidental VTE in oncology
patients is defined as “VTE identified in scans ordered
primarily for staging or restaging of malignancy” and the
terms “incidental” or “unsuspected” are recommended
against “asymptomatic” [7]. Patients with cancer and
incidentally diagnosed PE (i-PE) may be found to have
symptoms on closer review, or may genuinely have no PE
related symptoms [8,9]; however, the detrimental impact on
survival is the same as for PE diagnosed following clinical
suspicion [10]. Therefore, the standard of care remains to
treat all cancer patients with a PE (or a DVT) irrespective
of the manner of diagnosis. Most patients found to have a
PE, in the UK, spend 5–7 days in hospital. The aim of
admissions is to avoid potential complications such as
death, progressive right ventricular failure and major bleed-
ing while the patient is being established on anticoagulants,
even though only 4.5% will develop serious complications
during this time [11].
This ongoing practice may involve a significant number
of inappropriate admissions and, for cancer patients,
inappropriate anticoagulant management. The aim of this
project therefore, was to develop an evidence based and
protocol driven complex intervention (the i-PE pathway)
to manage cancer associated i-PE in an outpatient setting,
where safe and appropriate. A Working Group was
constituted to oversee and establish the intervention
based on the UK MRC Framework for developing complex
interventions [12].
In the current article we present the development and
implementation of the intervention, structured in three
phases: Phase 0 (theoretical underpinning), Phase 1
(modelling of the i-PE pathway - March 2009 to February
2010) and the pilot phase (Phase 2) which includes theinitial period of implementation, testing and real-time refine-
ment and optimisation (March 2010 to September 2011).
The described pathway is currently fully operational in
its presented iteration as part of Acute Oncology services
in our centre.
Methods
Phase 0. Theoretical underpinning
Published literature relevant to out-patient management
of cancer associated PE.
Unfortunately, although there are recommended pro-
tocols for the management of cancer associated throm-
bosis, including outpatient management of DVT, there is
very little guidance from existing literature to underpin
outpatient management of PE (incidental or otherwise).
A meta-analysis of trials of outpatient management of
PE [13] included only two small retrospective series with
cancer patients. The cancer patients were a ‘subgroup’ of
PE patients managed as outpatients [14,15] but with no
clear selection criteria. A further report on a larger cohort
of 473 patients with acute PE showed that 55% were treated
as outpatients. The decision not to admit was based on the
emergency department doctor’s clinical judgment. Reasons
to admit were “severe comorbidities” (46%) or hypoxia
(22%) [11]. No validated risk assessment tool in this and
most other studies was used prospectively to quantify
short term risk of death, and in almost all, coexisting active
cancer is assessed as necessitating admission.
Evidence on risk assessment tools
From the existing risk assessment tools the most robust
seemed to be the Pulmonary Embolism Severity Index
(Figure 1) [16]. This tool has 11 predictors scored from
+10 to +60 identifying five risk classes (I–V). All indices
are clinically generated and it is easy to administer. It
has been validated prospectively [17] found to be super-
ior to the GENEVA scoring system and it has low inter
assessor variability [18].
A recent randomised controlled (RCT) trial in non-
cancer patients with PE [19] which used this tool
showed no difference in outcomes for those with low
risk (score < 86) when managed as outpatients. Almost
all cancer patients however have a PESI score of more
than 100.
Two risk assessment tools specifically developed for
cancer patients have only very recently been proposed and
were not available at the time of the design of the interven-
tion. POMPE-C [20] and RIETE [21] both predict mortality
in patients with cancer and acute PE whilst POMPE-C
has been also compared with PESI demonstrating higher
prognostic accuracy in patients with active cancer [20].
These scores may become useful tools for prognostication
of cancer patients with i-PE and our group will aim to
assess these scores in this setting.
Figure 1 The Pulmonary Embolism Severity Index (PESI) scoring
tool – modified layout for patient scoring as used in our
pathway.
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patients
In the absence of contemporaneous guidance from the
National Institute for Health and Clinical Excellence
(NICE) establishing standards of care, data from retrospect-
ive local audits were assessed against the recommendations
of ASCO 2007 [22]. Current recommendations from
all relevant bodies are similar and rely heavily on a
published RCT [23].
The ASCO Recommendations for the management of
established VTE in cancer patients can be summarised
as follows: a) Low molecular weight heparin (LMWH)
is the preferred approach for the initial 5 to 10 days, b)
LMWH given for at least 6 months is also the preferred
approach for long-term anticoagulant therapy. Vitamin K
antagonists with a targeted INR of 2 to 3 are acceptable,
c) indefinite anticoagulant therapy should be considered
for selected patients with active cancer, such as those
with metastatic disease or those receiving chemotherapy
d) vena cava filters can be used in the presence of
contraidications for anticoagulation or recurrent VTE while
on adequate anticoagulation treatment. e) Anticoagulation
should be avoided in the presence of active intracranial
bleeding, recent surgery, pre-existing bleeding diathesis
such as thrombocytopenia (platelet count < 50,000/μL) orcoagulopathy and f) for elderly patients, anticoagulation is
recommended for established VTE as described for other
patients with cancer.
Audit findings and clinical activity data in relation to
contemporaneous evidence
i) Audit
The predicted annual caseload of i-PE for a trust of
the size of Hull and East Yorkshire Hospitals NHS
Trust (HEY) is between 50–55 patients. A
retrospective audit (spanning the period from
August 2006 to January 2008–18 months)
undertaken through the radiology department
reporting database of our cancer centre (Hull and
East Yorkshire Hospitals NHS Trust) identified 72
cases of incidental VTE (including visceral
thrombosis) of which 58 were i-PE [24]. We
estimated that this caseload represented 70-75% of
the incidence over this period. Thirteen of these
patients were already inpatients. Admission rate for
outpatient diagnoses was 33%. We observed that the
management of these patients was poorly
coordinated (as indicated e.g. by long times from CT
scan to treatment initiation) and was not uniform.
Only in 34 patients (58%) management was
assuredly consistent with ASCO recommendations.
ii) Data from patient registry
To establish a better understanding of the admission
practice for i-PE patients across HEY, immediately
prior the roll-out of the new pathway, a review of
the clinical activity of the preceding 12 months was
undertaken. Data was recovered from the Trust’s
registry database for the period spanning from April
2009 to March 2010. All patients coded for PE were
retrieved (345 patients) and the patients with the
diagnosis of i-PE were analysed. 28 patients with
cancer and i-PE diagnosed as outpatients had a
registered admission with a mean hospital stay of
5.7 days (range: 0–12)
Phase 1. Modelling phase
This phase aimed to clarify key elements (Table 1) for
the intervention and their interactions and make the
necessary adaptations for the pilot site. During this phase
the appropriate personnel to be involved in the project
multi-disciplinary management group were identified
and consulted.
Identification of training needs and implementation of
training plans
It was recognised that the implementation of the pathway
would need to be based on specific competencies of
Table 1 Phase 1 modelling
Elements Implementation
a) identification of training
needs and requirements/
i) Nurse Specialists: Formalised
training module (competency)
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specialists (CNSs) and CT radiographers.
i) Clinical Nurse Specialists (CNSs)
implementation of plans to
meet these needs ii) Radiographers: Case-review
training material
b) mapping of patient
pathways and flow
Flow charts









Key elements of the intervention.A new competency for CNSs for the management of
i-PE was introduced and ratified by the Trust
Nursing and Midwifery Training and Education
Forum. In the absence of existing literature or
training ‘package’, key training needs taking in to
consideration the lack of pre-existing competency,
were laid out in a consultation document by AM
and JP and further input was obtained from the
University of Hull school of nursing. A
comprehensive training schedule was produced that
required the nurse practitioner to demonstrate
knowledge and understanding through observation
and assessment by an identified supervisor. Amongst
the elements of the module are the understanding
and implementation of the risk scoring tool; key
cardio respiratory indices to be assessed; familiarity
with the prescription medication (Dalteparin) and the
recommended schedule (which includes a 25% dose
reduction after week 4). Key knowledge such as an
understanding of the adverse effects of Low Molecular
Weight Heparin (commonly bleeding risk but also
including the Heparin-Induced Thrombocytopenia)
was also incorporated. Key categories of patients that
would need immediate clinical referral out with the
pathway were also identified (e.g. patient with GI
bleed or brain metastases). Once these competencies
were finalised a training module was developed which
was mapped to the Hull & East Yorkshire Hospitals
NHS Trust Systematic Training and Education
Programme Level 2 (STEP 2) [25] (Additional files 1
and 2 show the supervisor and the practitioner packs
as mapped to the STEP 2). These CNSs for the
purposes of the manuscript are called ‘assessors’.
Permission to use the PESI score [16] within the
context of this service was obtained from Prof.
Drahomir Aujesky (personal communication).
ii) Radiographers
The competency requirements of CT radiographers
have been developed according to the document
“The NHS Improvement Plan Putting People at the
Heart of Public Services” [26]. In this document,
incidental findings are described as “findings that are
unrelated to the clinical indication for the imaging
examination performed” and include a specific
category of “emergency findings” defined as
pathologies which alter patient management before
their next outpatient appointment. Examples of
emergency findings are pulmonary emboli,
abdominal obstruction, destructive bone lesions,
pneumothorax and brain metastases. In specificrelevance to the incidental PE management pathway
regular teaching is implemented to enhance
identification of PE at this ‘first-pass’ opportunity of
the patient in the department. Case review training
material, such as a DVD of typical cases of PE
distribution, has been produced to enhance learning.Mapping of patient pathways and flow
Establishment of the new pathways was supported from
within existing resource in HEY. Firstly a working group
(WG) with operational responsibility was formed. The
WG remit was to establish an evidence-based, protocol-
driven complex intervention following UK MRC guid-
ance and implement it for patients diagnosed with an i-
PE. Continuing oversight of the project was provided by
(MJ) who had previous expertise in the development of
a complex intervention using this guidance. This WG
met monthly and was attended by acute oncologists (at
least one of LO’T, GB, AM), radiologist (GA), radiog-
rapher (AS), assessors (at least one of JP, ME, JH or SD),
data manager and representative from the community
based DVT service. A project specific database was written
(GB) and a data manager (KM or VW) within radiology
was tasked to collect and collate the data (initials corres-
pond to contributors mentioned in the authors list and the
acknowledgements list).
The WG formulated the complex intervention that in-
cluded the mapping of all pathways that lead from radi-
ology to the end practitioner (assessor) who was to
initiate management of the patient. The practitioner
would assess the patient, administer appropriate ques-
tionnaire(s), initiate the treatment, refer the patient into
the appropriate clinic for follow up, or arrange medical
review/admission, inform community/GP practice and
send information to the data manager for data recording
(Figure 2).
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procedures
The patient documentation used by the Chemotherapy
Nurse Specialist Team (assessors) when assessing a
newly referred patient includes a demographic sheet with
observations performance status and weight and space
for communicating the outcome of the assessment, a
history checklist to determine patient history and a
symptom questionnaire for the patient to complete
(Additional file 3 shows the data-sheet and patient symp-
tom questionnaire used).
A Pulmonary Embolism Severity Index (PESI) score form
is also completed (Figure 1). Other documentation used in-
cludes a data sheet, Dalteparin prescription and a GP letter.
Follow –up and data collection
Initial data are collected during patient assessment by
the assessors and entered onto the data base by the Data
manager. Further data collection was planned to happen
at opportune but not predefined intervals during the
proposed period of LMWH treatment, to include early
(day 0 and 7) platelet counts, capturing dose ‘step down’
at week 4, LMWH discontinuation, schedule-dose alter-
ation or agent alteration (e.g. warfarinization), complica-
tions (bleeding, painful abdominal wall bruising) and
quality of life concerns.
Dissemination/education
The Clinical Practice Development Committee reviewed
the pathway (December 2009). Medical staff and allied
professionals were informed of the complex intervention
through a series of internal meetings prior to the project
commencement in March 2010 and regular updates
were communicated through existing specialist forums
(radiology, nursing and oncology service meetings) when
changes to the intervention were implemented.
Summary iteration of resultant complex intervention
entitled “The i-PE outpatient pathway”
The i-PE pathway resulting from the theoretical underpin-
ning and modelling phase is summarised:
i) From Scanner to Assessor
As per the pathway, an incidental PE can be
identified at two stages:
a) ‘First Pass’: By the scanning radiographer, who
then brings it to the attention of the radiologist.
Patient enters pathway on day of scan.
b) ‘Reporting Stage’: By the reporting radiologist.
Patient enters pathway at the time of formal
review of the CT, usually a few days after scan.
In practice all out patient scans are reviewed by
radiographer prior to the patient leaving the
department aiming to identify any emergencyfindings. When a PE is identified by the
radiographers this is brought to the attention of the
CT supervising radiologist and if the finding is
verified, action is taken according to the pathway
recommendations to ensure correct management of
the patient. A total of four discrete notification/
referral pathways were established to cover working
hours and out-of-hours identification of i-PE during
scanning (Radiographer) or during reporting
(Radiologist) respectively (flow charts depicting
these pathways can be found in Additional file 4).
ii) From Practitioner to Community (or admission)
The telephone referral from the radiologist is
received by the assessors and the patient is seen
within 24 hours of the referral being received. The
patient is assessed, PESI score recorded and all
relevant documentation completed.
For patients that are risked assessed and presumed
to have a high potential risk of 30-day mortality
[PESI score (> 125)] [16] or patients with abnormal
indices on the cardio-respiratory criteria of the PESI
scoring system and/or new symptoms an acute
oncology medical review is undertaken and
admission considered.
When the patient is deemed eligible for out-patient
care, he/she or his/her carer is trained how to inject
low molecular weight heparin (LMWH) and the
patient is provided with the first 4 weeks of treatment.
This process takes approximately one hour. All
patients undergo blood sampling for a full blood
count and a biochemical profile including renal
function tests at baseline and repeated seven days
after treatment is initiated. Prior to leaving the
hospital the patient is given a follow up appointment
with their treating clinician. A letter, containing a
treatment plan, is faxed to the patients’ general
practitioner (GP) informing them of the i-PE and
the treatment initiated. The hospital provides the
patient with enough LMWH, (Dalteparin) at a dose
of 200 iu/kg to last them for 4 weeks. After 4 weeks
the dose is stepped down to 150 iu/kg as per
product recommendations and the patient continues
on this dose for the next 5 months in accordance
with current guidance. It is expected that after the
first 4 weeks, the patients’ GP will initiate the step
down dose and provide future injections until
treatment is discontinued or the patient is
warfarinised.
The pathway also considers the i-PE patient who,
according to the diagnosing radiographer’s
opinion, is unwell and should be seen
immediately. This is specifically relevant for
scanning lists that are out of hours or on
weekends as the intervention is available only
Figure 2 Diagram of the i-PE pathway. Patient flows in blue arrows. Data flow in dashed pink arrows.
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oncology referral pathway is recommended and
incorporated in the pathways.Results and discussion
Phase 2: Pilot. Real time re-modelling, refinement and
optimization of the complex intervention
From March 2010 to September 2011, 82 patients
had been managed using the i-PE pathway. Data on
this group have been presented in abstract form [27]
and demonstrate marked improvements in admission
rates and guideline adherence.
In the regular WG meetings, ongoing modelling of
the pathway was possible in response to problems
and deviations arising in practice, resulting in real-
time remedial action.Patients managed independently of the i-PE pathway
HEY operates two CT diagnostic units in its two major sites
(Hull Royal Infirmary-HRI and Castle Hill Hospital-CHH)
with the Accident and Emergency (A&E) and Oncology
departments on different sites, six miles apart. In addition,
since the incidence patterns of i-PE are unpredictable
the assessors cannot reserve clinic time. Pathway patients
are therefore seen alongside the usual daily workload.
In practical terms immediate assessor availability is not
universally (100%) possible.
This operational structure was identified by the WG
as the main underlying reason behind the cases where
patients failed to be referred properly and be managed
within the pathway. In total, 6 such patients were identified.
Three patients were admitted directly via A&E and the
assessors were not informed. Two patients were already
receiving LMWH, were managed by their treating clinician
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diagnostic investigations for cancer and was managed by
the diagnosing clinician.
Remedial action In order to improve the co-ordination
of patients diagnosed with i-PE at the time of scanning,
the radiology pathways were adjusted to give better dir-
ection to the radiologist and reinforce the i-PE pathway
referral algorithms, with care to cover circumstances
when the assessors are not immediately available or the
distance between the HRI CT site and Oncology in CHH
(where the nurse practitioners are based) is a factor for
immediate review by the team. These adjustments enabled
patients who were asymptomatic to be allowed home and
invited back for assessment, rather than being admitted.
For patients who are symptomatic, especially when diag-
nosed out of hours, the pathway was modified to explicitly
instruct radiologists to arrange the review of the patient
by the Acute Oncology out of hours service in the Oncol-
ogy unit and not the standard A&E service so that cases are
rapidly and centrally assessed and managed according to
the set guidelines. All such cases are also reviewed by the
recognised assessors at the earliest convenience and data is
captured as per the pathway.
Failures of compliance with dosing protocol
After the first three months of the pathway being
implemented the patients referred onto the pathway were
contacted to ensure that their dose of Dalteparin had been
stepped down. It was discovered that GPs were not step-
ping down the dose of heparin after the first 4 weeks as
instructed. On an interim survey of the first 40 patients
managed with the pathway, the rate of dose de-escalation at
four weeks was 40% (n = 14, no data for 5 patients).
Remedial action This was addressed by adjusting the
wording in the GP letter to highlight the date of projected
step down. Furthermore patients were educated to expect/
request the step down at 4 weeks.
Unreliable capture of follow up data
It became apparent that reliable toxicity data or information
whether the patients continued on LMWH were difficult
to obtain from the source notes or the hospital patient
information system.
Remedial action The initial documentation was modified
to gain consent from patients for the assessor to contact
them by telephone at 3 months and 6 months.
Selection challenges from the use of the PESI tool
Even before the intervention commenced the WG
recognised that the use of a generic pulmonary embol-
ism scoring system in a specific subgroup of patients(i.e. cancer patients with i-PE) could pose particular
selection challenges, the nature of which however was
difficult to predict. Prospective collection therefore of indi-
ces that are known to have predictive properties for cancer
was included (e.g. performance status, stage of disease).
The interim analysis of the data (first 82 patients) revealed
a significant overestimation of mortality risk by the PESI
in this subgroup of patients [27].
Remedial action Modification of the risk assessment
tool was done to a) add a ‘new symptoms’ index that
the emerging data seemed to suggest was a stronger
predictor of worse outcome and b) allow greater dis-
charge latitude to the assessors based on the audit data
of the first 82 patients.
‘First pass’ Identification of i-PE
Given that identification of i-PE by radiographers
was a major component of the service improvement
and reinforced within the training competency a post-
implementation prospective audit was undertaken.
In our recently published analysis [27] we found that i-PE
was identified at the time of scanning by the radiographers
in 56 (71%) of 79 patients (Table 2). Among the 23 cases
missed by radiographers, n = 17 (74%) were segmental or
sub-segmental and n = 7 (26%) were central or lobar.
The reasons for this ‘miss rate’ were found to include
the following: a) In the busy scanning environment
radiographers can be distracted by telephone calls, control
room queries, and pressure to scan the next patient, there-
fore omitting the review or not reviewing with sufficient
time/scrutiny. b) Inexperienced staff may miss PE due to
lack of experience/education.
Also noted is that the i-PE pathway received three in-
appropriate referrals from radiology at the same period:
a) one did not have a PE, b) one was referred for further
investigations and c) one patient was a suspected but
not verified DVT and not PE.
Remedial action Processes such as ongoing education
of radiographers, improved and more frequent feedback
and training in a systematic method of reviewing the scans
is being implemented. Detection rates will be audited
again in a future cohort. To reduce false positives a formal
CT report of the PE to be dictated and made available for
review by the assessor prior to patient assessment.
Observations on Phase 2 of the intervention
This pathway has standardised practice for the care and
management of this particular patient group. Early repeat
audit data indicate an important increase in the number
of patients safely managed at home rather than in hospital
allowing not only cost savings for the institution, but, more
importantly, patient benefit in prevention of unnecessary
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improved communication between healthcare professionals
and hence the quality of data acquisition Confidence gained
from working in this setting has also motivated the staff to
seek training in further skills. All the assessors are including
the prescription of LMWH in their training as supplemen-
tary prescribers while continued education of radiographers
to improve ‘first pass’ identification of PE is ongoing and
has resulted in the production of a training DVD. Prelimin-
ary key findings have been that 71% of patients were diag-
nosed by radiographer on the same day of scanning and the
majority of patients 57% are reviewed the same day as the
CT scan (range 0–21) [27]. Adherence to guidelines has
also improved markedly. We recorded adherence to ASCO
2007 guidelines of 98% [27] in the group of patients man-
aged prospectively on this pathway compared to 58% from
our retrospective audit.
The development and implementation process has
focussed on the specific issues relating to our NHS
Hospital Trust nevertheless our experience has led to a
deeper understanding of the ‘modular’ transferable ele-
ments for adaptation to and implementation in other
NHS hospital environments.
Resource utilization is also likely to be improved and
possible cost-savings realised; however this work did not
have health economics planned and although simple
retrospective calculations based either on the cost of
occupying a bed in the Trust or on the national tariff for
uncomplicated PE may suggest significant cost savings,
one has to be critical of ad hoc methodology employed
to these data. This service model would need to be
exposed to a proper resource utilization analysis within
a prospective trial-setting designed to establish the true
value/resource implication of a restructured service that
embraces this intervention. Similarly although we believe
that the avoidance of admission should enhance the patient
experience we do not have any comparative evidence to
show this. For example it is possible that for some patients
at least the anxiety of being discharged with a ‘clot in the
lungs’ may be significant and an admission for them may







Central PE 20 15 (75)
Lobar PE 9 7 (78)
Segmental PE 41 29 (70)
Subsegmental 9 5 (56)
* Includes 79 of 82 patients presented in ISTH 2012 [27]. Information regarding
identification of PE by the radiographer was missing in 3 patients (4%).studies to capture these elements between the two service
models would be needed.
Conclusions
We have developed and piloted a complex intervention
for the outpatient management of i-PE in cancer pa-
tients, based on MRC UK Guidance. This complex inter-
vention has core components which can be mapped and
adapted for use in other NHS organizations. The pilot
phase has demonstrated improved flow of patients through
departments, improved communication between profes-
sionals and patients, and improved adherence to evidence
based guidelines. Initial findings suggest that using this
intervention most patients can be safely and effectively
managed in an outpatient setting with improvement of
quality of care.
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